Trial Profile
Planned adaptive design phase II trial of interleukin 24 gene therapy in patients with recurrent head and neck cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2014
Price :
$35
*
At a glance
- Drugs Interleukin 24 gene therapy-MultiVir (Primary) ; Antineoplastics
- Indications Head and neck cancer
- Focus Registrational; Therapeutic Use
- Sponsors MultiVir
- 03 Mar 2014 New trial record